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pregabalin.  
Objectives: In order to describe and map what is known about misuse and 
abuse of pregabalin, a scoping review of available published literature was 
undertaken.  
Methods: A scoping review methodology was used to identify and map 
available literature on misuse and abuse of prescribed and diverted 
pregabalin.  
Results: Four themes emerged on the misuse and abuse of pregabalin: (1) 
Abuse potential, (2) Prevalence of abuse, (3) Risk and predisposition and 
(4) Consequences of abuse. Fifty four  records were reviewed and charted.
Of note was the dearth of research on the topic prior to 2005, with
increased interest in pregabalin abuse potential from 2010 onwards.
Conclusion: Available literature supports concern around abuse potential of
pregabalin, especially among patients with a history of substance abuse.
Prescribers should adopt more rational prescribing.
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Abstract 
Background: Prescribing of pregabalin is increasing worldwide with public health concerns 
centring on misuse and abuse of prescribed and diverted pregabalin. 
Objectives: In order to describe and map what is known about misuse and abuse of 
pregabalin, a scoping review of available published literature was undertaken. 
Methods: A scoping review methodology was used to identify and map available literature on 
misuse and abuse of prescribed and diverted pregabalin. 
Results: Four themes emerged on the misuse and abuse of pregabalin: (1) Abuse potential, (2) 
Prevalence of abuse, (3) Risk and predisposition and (4) Consequences of abuse. Fifty four 
records were reviewed and charted. Of note was the dearth of research on the topic prior to 
2005, with increased interest in pregabalin abuse potential from 2010 onwards. 
Conclusion: Available literature supports concern around abuse potential of pregabalin, 
especially among patients with a history of substance abuse. Prescribers should adopt more 
rational prescribing. 
Keywords: Pregabalin, Abuse, Misuse, Dependance, Prescription drug 
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Introduction 
By definition, any medication can be misused, but few have abuse potential, and particularly 
those with mind-altering or body-shaping properties (Hughes et al., 1999). The most commonly 
abused prescription medications worldwide are stimulants (methylphenidate) used for treating 
Attention Deficit Hyperactivity Disorder (ADHD), central nervous system (CNS) depressants 
such as sedatives (benzodiazepines) (National Institute on Drug Abuse (NIDA), 2014) and 
anticonvulsants (pregabalin) (Loftus & Wright, 2014). The risk of dependence on such 
prescription drugs increases when they are used in ways other than prescribed, e.g., at higher 
doses, by different routes of administration, or with a combination of alcohol or other drugs 
(NIDA, 2014). Adverse health and social consequences of prescription medicine abuse and 
dependence are steadily worsening worldwide, and are reflected in increased treatment 
admissions, emergency room visits, and overdose deaths from drugs such as opioids, CNS 
depressants, and stimulants (NIDA, 2014). This is particularly evident in the United States (US), 
currently experiencing an opioid crisis. In Europe, the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) and European Medicines Agency (EMA) currently exchange 
warning trend information around abuse of medicinal products, and with key examples including 
(cafentanyil, pregabalin, etaqualone, zopiklone, phenibut, gabapentin, and tropicamide) 
(EMCDDA-Europol, 2013; EMCDDA, 2014).
Of interest for this scoping review is the drug known as pregabalin which is an analogue of the 
gamma-aminobutyric acid neurotransmitter, and approved for the treatment of partial epilepsy, 
generalized anxiety disorder, peripheral and central neuropathic pain, and fibromyalgia 
(Papazisis & Tzachanis, 2014). Pregabalin decreases central neuronal excitability by binding to 
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an auxiliary subunit (α2-δ protein) of a voltage-gated calcium channel on neurons in the central 
nervous system and reduces the release of several neurotransmitters, including glutamate, 
noradrenaline, and substance P (Schwan et al., 2010). The potential for abuse and/or physical 
dependence on pregabalin was originally assessed to be low at the time of marketing 
authorization (Schwan et al., 2010). However, it was noted that euphoria occurred as an adverse 
event in clinical trials among 1–10% of patients depending on dose, compared with 0.5% for 
placebo (Schwan et al., 2010). Of particular concern is that global prescribing of pregabalin is 
increasing, with total sales projected to reach $3.3 billion by 2018 (Mackey, 2010). Pregabalin is 
controlled in Jordan, Norway and in the USA by the Jordan Food and Drug Administration, the 
European Medicines Agency and the American Drug Enforcement Administration report 
(Blommel & Blommel, 2007; Bramness et al., 2010; Jordan Food and Drug Administration, 
2017). Diverted and off label use of pregabalin is also on the increase in Europe (EMCDDA-
Europol, 2013; EMCDDA, 2014) and in the Middle East (Al-Husseini, et al., 2017). Profiles of 
pregabalin abuse generally involve individuals with a history of abuse of other medications 
(Papazisis & Tzachanis, 2014; Häkkinen et al., 2014). In order to describe and collate what is 
known about misuse and abuse of pregabalin, a scoping review of available published data on 
misuse and abuse of prescribed and diverted pregabalin was undertaken.  
Methods 
Scoping review methods are increasingly popular as an accepted review approach (Arskey & 
O’Malley, 2005; Hidalgo Landa et al., 2011) and are used to “map the literature on a particular 
topic or research area and provide an opportunity to identify key concepts; gaps in the research; 
and types and sources of evidence to inform practice, policymaking, and research.” Daudt et al. 
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(2013). This form of descriptive synthesis is generally used to provide descriptive summaries of 
the literature, across a broad range of methodologies and study designs, summarize and publish 
findings of the research, and identify gaps in the current literature (Arskey & O’Malley, 2005; 
Brien et al., 2010; Rumrill et al., 2010). The scoping review was underpinned by the research 
question ‘ what do we know about the misuse and abuse of pregabalin?”. The research team 
adopted the five stage method as developed by Arskey and O’Malley (2005) which included: (1) 
identifying the essential research question, (2) searching for similar studies, (3) study selection, 
(4) charting the data, and (5) collecting, summarizing, and recording the results.
A thorough and systematic search of literature (1990-2017) was conducted by the team  using the 
following university databases: Science Direct, Electronic Library of Medicine, Hinari, Google 
Scholar, Cochrane Library, and PubMed. A comprehensive list of search terms was created by 
the team, which consisted of two pharmacists and an addiction/public health specialist. Searches 
combined the terms “pregabalin” with “abuse,” “misuse,” “dependence,” and “prescription 
drug.” For the purposes of this review, abuse was defined as the use of a drug for a non-medical 
reason (e.g., mental altering effect) and misuse as the use of a drug for a legitimate medical 
reason  but wrongly used either in terms of dose or duration (Hughes et al., 1999). The team of 
three authors screened literature titles and abstracts to determine their inclusion status. Full text 
articles were reviewed and screened independently to ensure inclusion.  
References were managed by the citation manager Endnote®. This software promoted the 
recording and organization of all related literature. This allowed cross-monitoring of data 
records, removal of duplicates, and extraction of information from the papers contained in the 
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review. The initial search identified 1,320 articles and excluded animal studies, duplicates, those 
not in the English language, articles where full text was not available, and lack of relevance 
specifically to the misuse and abuse of pregabalin. The disagreements of the relevance of data 
were resolved through discussion. (Figure 1). 
Insert Figure 1 about here 
A charting exercise was conducted by the team and was used to identify specific themes  
pertaining to misuse and abuse of pregabalin (Bergin et al., 2015). 
Results 
Fifty four  records were reviewed and charted. Of note was the dearth of research on the topic 
prior to 2005, with increased interest in pregabalin abuse potential from 2010 onwards. Eighteen 
clinical case reports of pregabalin misuse or abuse were identified, and were from the US 
(Filipetto et al., 2010), Turkey (Yargic & Ozdemiroglu, 2011; Aksakal et al., 2012; Aldemir et 
al., 2015; Sonmez, 2015), Austria (Yazdi et al., 2015), France (Driot et al., 2016), Greece 
(Papazisis et al., 2013), Germany (Olaizola et al., 2006; Grosshans et al., 2010; Skopp and & 
Zimmer, 2011; Gahr et al., 2013 a), Italy (Carrus & Schifano, 2012), United Kingdom (Braga & 
Chidley, 2006; Wood et al., 2010), India (Tandon et al., 2013), Ireland (Osman & Casey, 2014), 
and Lebanon (Halaby, 2015). Thirty six publications were obtained as peer reviewed journal 
articles from Germany (Gahr et al., 2014; Bonnet and Scherbaum, 2017), United Kingdom 
(Schifano et al., 2011; Baird et al., 2013; Kapil et al., 2014; Loftus & Wright, 2014; Eastwood & 
Davison, 2016), USA (Zacny et al., 2012; Papazisis & Tzachanis, 2014; Wilens, 2014), Finland 
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(Kriikku et al., 2014), Jordan (Wazaify et al., 2016; Al-Husseini et al., 2017),  and Italy 
(Martinotti, 2012), and as reports from Germany (Gahr et al., 2013 b; Grosshans et al., 2013; 
Cossmann et al., 2016; Freynhagen et al., 2016), United Kingdom (Millar et al., 2013; Schifano, 
2014; Asomaning et al., 2016), Sweden (Schwan et al., 2010; Bodén et al., 2014), Denmark 
(Schjerning et al., 2016 a; Schjerning et al., 2016 b), USA (Herman et al., 2012; Wills et al., 
2014; Evoy et al., 2017; Dart et al., 2017), France (Bossard et al., 2016), Finland (Häkkinen et 
al., 2014; Heikman et al., 2016), Norway (Sugandiran & Bramness, 2014), Switzerland 
(Mutschler et al., 2016; Suardi et al., 2016), and Italy (Chiappini & Schifano, 2016). A summary 
is presented in Table 1.  
Insert Table 1 about here  
Four themes emerged from the charting exercise of data collected on the misuse and abuse of 
pregabalin: (1) Abuse potential, (2) Prevalence of abuse, (3) Risk and predisposition and (4) 
Consequences of abuse. 
Abuse potential  
Abuse of pregabalin (and gabapentin) occurs in several forms, by using the drug above the 
approved recommended doses (Loftus & Wright, 2014), or with opiates and other drugs (for 
example benzodiazepines) to potentiate the effect of the latter (Baird et al., 2013; Schifano, 
2014). Pregabalin has also been claimed to be useful in the treatment of nicotine dependence, but 
it is important to note that pregabalin has some abuse potential and should be used cautiously 
especially in dependent individuals (Herman et al., 2012).  
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In Sweden, a study was conducted to measure the abuse liability of pregabalin by applying a 
Bayesian data-mining algorithm to the 16 available reports of possible abuse or dependence of 
pregabalin in the Swedish national register of adverse drug reactions (SWEDIS). This study 
concluded that more research was warranted to characterize its extent and nature (Schwan et al., 
2010). Bossard et al., (2016) provided a disproportionality analysis of all currently available 
pharmacovigilance studies and reported pregabalin was not abused more intensely than 
amitriptyline, an antidepressant drug without abuse liabilities, and also found that pregabalin was 
abused significantly less than clonazepam, a drug with evident abuse liability (Bossard et al., 
2016).  While in Norway, the Norwegian version of M.I.N.I International Neuropsychiatric 
Interview was used to identify pregabalin abuse or dependence, according to DSM-IV diagnosis. 
Five of the six subjects achieved the DSM-IV criteria for pregabalin dependence, and with all 
five patients diagnosed with co-morbid psychiatric conditions. The study underscored how 
iatrogenic dependence in patients with chronic disease occurs in the case of pregabalin 
(Sugandiran & Bramness, 2014). In Germany, urine specimens were taken from patients with 
opiate dependence and other addiction disorders, and screened for pregabalin to measure its 
abuse potential in these patients. Only 12.1% of specimens were positive for pregabalin taken 
without medical indication (Grosshans et al., 2013).  
Four systematic reviews on the abuse potential of pregabalin, and investigated the preclinical, 
clinical, and epidemiological data concerning abuse of pregabalin (Schjerning et al., 2016 b); the 
pharmacological characteristics of pregabalin abuse (Papazisis & Tzachanis, 2014); extent of 
gabapentinoid abuse, characteristics of typical abusers, patterns of abuse, and potential harms 
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8 
(Evoy et al., 2017) and evaluation of gabapentinoid dependence risk (Bonnet and Scherbaum, 
2017). Bonnet and Scherbaum (2017) found very few cases with gabapentinoid-related 
behavioural dependence symptoms (ICD-10) in patients without a prior abuse history. In Italy, 
an observational study revealed that pregabalin liability for abuse was an issue of concern, 
especially in doses prescribed above 600 mg/day more commonly seen in psychiatric conditions 
such as anxiety disorder (Martinotti, 2012). Two studies originated in the US. The first, by Zacny 
et al. (2012) explored the subjective effects of pregabalin used alone and pregabalin used with 
co-medication (various doses) in 16 healthy volunteers, and aimed to investigate if pregabalin 
used with co-medication changed the subjective effects of opioids (oxycodone). The second, 
assessed patients in a detoxification center and reported that a small proportion (7%) of opioid 
dependent patients were misusing pregabalin (Wilens et al., 2014).  
Several case reports illustrated the abuse of pregabalin in patients prescribed for medical 
conditions such as pain management, generalized anxiety disorder (GAD), and treatment of 
neuropathic pain (Filipetto et al., 2010; Aksakal et al., 2012; Aldemir et al., 2015) and 
particularly evident among those individuals with previous histories of poly-substance abuse. 
Patients developed drug seeking behaviour and withdrawal symptoms when stopping or 
decreasing the dose of pregabalin (Gahr et al., 2013 a; Halaby, 2015). Two cases had no history 
of drug abuse but reported craving for pregabalin (Driot et al., 2016). A case of a patient with 
borderline personality disorder (Gahr et al., 2013 a) and history of alcohol abuse reported that 
pregabalin had the potential to stimulate the development of habit forming and dependence type 
behaviours. Two other case reports described the abuse of pregabalin as when used in high 
doses, and when crushed formulations of pregabalin were smoked, and described when ingested 
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the incidences of myositis (Carrus & Schifano, 2012). Three cases reported abuse of pregabalin 
in patients with a known history of drug abuse (Grosshans et al., 2010) and with one observing 
that that pregabalin had a lower abuse potential than benzodiazepines (Yargic & Ozdemiroglu, 
2011). Upon discontinuation of pregabalin, patients suffered from withdrawal symptoms and 
were classified using the DSM-5 criteria for the pregabalin use disorder (Sonmez, 2015).  
Prevalence of abuse  
Three studies measured the prevalence of pregabalin use at higher than recommended dosages. 
One study derived from the Swedish national registry reported that 8.5% of patients were 
dispensed pregabalin at high doses, and that epileptic patients in particular were more likely to be 
dispensed pregabalin at higher than recommended daily dosages (Bodén et al., 2014). The 
second study was based on the Danish nationwide registry and reported that 4,090 pregabalin 
users (9.6%) out of the total of 42,520 were treated with more than 600 mg/day for 6 months. 
Males and patients with prescriptions of antipsychotics and benzodiazepines were correlated 
with increased risk of use of higher than recommended dosage (Schjerning et al., 2016 a). The 
UK Drug Utilization Study (DUS) analyzed pregabalin prescription data from the UK Health 
Improvement Network primary care database and recently reported that only 1.0% of patients 
were prescribed pregabalin above maximum recommended doses of 600 mg/day (Asomaning et 
al., 2016).  
The database of the Federal Institute for Drugs and Medical Devices (BfArM) in Germany 
recorded a total of 55 reports of pregabalin abuse by males and patients with a history of 
polytoxicomania, and which were correlated to risk of developing addictive behaviors in relation 
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10 
to pregabalin (Gahr et al., 2013 b). A cohort study of older patients in a German hospital (400 
randomly selected cases) reported that a fifth of the cohort were found to be dependent on 
nonopioid analgesics, and with one case identified with a history of dependence on gabapentin 
(Cossmann et al., 2016).  
In the UK, a review of all cases admitted to the emergency departments after pregabalin abuse 
revealed that 10 patients presented to the ED following recreational pregabalin abuse with 
dosages ranging from 500–1400 mg (Millar et al., 2013). Also, an Internet-based survey was 
conducted to evaluate the prevalence, frequency, and sources of misuse of the GABA analogues 
(baclofen, gabapentin, and pregabalin). The prevalence of misuse was 1.3% for baclofen, 1.1% 
for gabapentin, and 0.5% for pregabalin (Kapil et al., 2014). This study highlighted the need for 
further work to understand the reasons for misuse in order to target appropriate harm-reduction 
activities (Kapil et al., 2014). Pregabalin use among opioid-addicted patients in Switzerland were 
assessed in 109 cases and quantified using 3-month hair toxicology analysis (Mutschler et al., 
2016). None of the participants reported pregabalin use and pregabalin was undetectable in all 
samples. These findings contrast sharply with reports of pregabalin misuse by opioid-dependent 
patients in other countries (Mutschler et al., 2016).  
Risk and predisposition 
A meta-analysis study was conducted in regards to all published cases to measure the risk factors 
leading to the addictive behaviors, and the results proposed that males, young age, and current or 
previous substance abuse represent risk factors that contribute to patient vulnerability to adopting 
pregabalin correlated addictive type behaviors (Gahr et al., 2014; Sonmez, 2015). Reviews of 
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patient characteristics report that patients with past poly drug abuse histories abuse pregabalin 
(Heikman et al., 2016; Suardi et al., 2016).  Availability also remains a risk factor. In countries 
such as Jordan, where the drug is available off prescription, pregabalin abuse is rising (Wazaify 
et al., 2016). Online sourcing of pregabalin additionally continues to represent a challenge 
(Schifano et al., 2011).  
Hence, cautious use of pregabalin is advised in patients who have a history of substance abuse 
(Schifano, 2014). Pregabalin is also used to treat substance dependence. An internet search of all 
published data regarding the role of pregabalin in treating withdrawal symptoms associated with 
multiple drug types and alcohol, resulted in limited data supporting pregabalin for managing 
withdrawal symptoms and requires further studies to determine pregabalin efficacy and safety 
(Freynhagen et al., 2016). Pregabalin as treatment modaility for nicotine addiction reported  
mixed outcomes, in that it doesn’t reduce smoking behaviours, but weakens withdrawal 
symptoms and the subjective ratings of “liking” smoking (Herman et al., 2012).  
Consequences of abuse  
Reports of abuse for intoxication purposes generally describe insufflation of crushed pregabalin 
tablets (Carrus & Schifano, 2012; Millar et al., 2013). User experiences were described in a 
qualitative study conducted in Jordan, where the positive outcomes of pregabalin use centered on 
its effect in making users sociable and talkative with others (Al-Husseini et al., 2017). Pregabalin 
was consumed in higher doses to reach intoxication and appeared enhanced when smoking 
cigarettes or when combining with sweet drinks (Al-Husseini et al., 2017). Enhancement of 
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12 
sexual desire at higher doses was reported in a patient with a history of psychoactive drug abuse 
(Osman & Casey, 2014).  
According to the National Poison Data System in the US, the rate of pregabalin abuse cases 
increased 4.3 fold in the period 2006 to 2014, with medical outcomes ranging from moderate 
health effects to death (Dart et al., 2017). Adverse drug reactions were more frequent in 
pregabalin abuse in comparison to gabapentin (Chiappini & Schifano, 2016). The Electronic 
Poison Center data in the US reported on 23 cases of pregabalin abuse contributing to impaired 
mental status (Wills et al., 2014). One case reported  a patient suffering from psychotic 
symptoms with rhythmic EEG-changes after taking pregabalin at normal doses (Olaizola et al., 
2006).  Continuous use of pregabalin contributed to deliberate self harm in one case (Tandon et 
al., 2013). An intentional overdose case reported a patient taking pregabalin and lamotrigine and 
highlighted the need for clinical awareness around the adverse effects in both therapeutic and 
toxic doses of pregabalin (Braga & Chidley, 2007). ).  “Black outs” contribute to risk of fatal 
overdose (Häkkinen et al., 2014; Lyndon et al., 2017). Another report concluded that there was 
an effect of pregabalin on the heart as the patient who had used for 8 months experienced 
complete atrioventricular (AV) block on an ECG (Aksakal et al., 2012).  
A study on the proportion of fatalities related to pregabalin or gabapentin abuse was conducted 
in all medicolegal death cases in Finland. A total of 48.1% of pregabalin positive cases were 
associated with drug abuse, and were fatal when mixed with opioids (Häkkinen et al., 2014). 
Most fatalities occur as a result of poly drug abuse, with high levels of up to 226 mg/L 
(Eastwood & Davison, 2016). Post mortem blood was analysed by Eastwood & Davison (2016) 
to obtain pregabalin therapeutic concentration and fatal ranges. A total of 70 post-mortem blood 
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13 
samples of pregabalin was detected over a two-year period. Pregabalin concentrations ranged 
from 0.05 mg/L to 226 mg/L in the group as a whole and in one case a pregabalin concentration 
of 76 mg/L was detected to be the possible cause of death as no other drugs of importance were 
detected (Eastwood & Davison, 2016). Wood et al., (2010) reported a serum pregabalin 
concentration of 66.5 mg/L with the patient treated with supportive care alone (Wood et al., 
2010). A concentration of 25 pg pregabalin/mL serum analyzed by LC/MS/MS following 
precipitation of serum proteins was reportd by Skopp & Zimmer (2011). Lastly, a study in 
Finland  measured the amount, nature of pregabalin abuse, and serum pregabalin levels of the 
drivers apprehended for driving under the influence of drugs (DUID) in 2012. Pregabalin was 
discovered in 206 samples in the study, with 50% of the cases reporting a serum concentration 
higher than the typical therapeutic range (Kriikku et al., 2014). 
Discussion 
This review has mapped the available literature around what is currently known around misuse 
and abuse of pregabalin. It underscores the phenomenon of pregabalin misuse and abuse as a 
more recent trend, as evident in the increased literature available since 2010. Ultimately it 
highlights the need for enhanced pharmacovigilance and surveillance of pregabalin abuse trends, 
despite its more recent emergence as a drug to be monitored both on and off label (EMCDDA-
Europol, 2013; EMCDDA, 2014).  
Our mapping of the literature highlights the diverse range of those patients at risk of pregabalin 
abuse and dependence, and evident in certain special populations such as patients with legitimate 
therapeutic need and using it above the recommended dosages, and vulnerabilities particularly 
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14 
concentrated among those with a history of psychiatric disorder, opioid dependence and poly-
substance abuse or dependence (Filipetto et al., 2010; Schwan et al., 2010; Canadian Agency for 
Drugs and Technologies in Health, 2012; Carrus & Schifano, 2012; Gahr et al., 2013 a; Baird et 
al., 2013; Tandon et al., 2013; Wilens et al., 2014; Grosshans et al., 2013; Osman & Casey, 
2014; Aldemir et al., 2015; Driot et al., 2016). Risks additionally centre on over the counter or 
off label availability (Wazaify et al., 2016), online retail (Schifano et al., 2011) and in the 
prescribing of high doses to patients (Bodén et al., 2014).  
Pharmacodynamics of pregabalin may have direct/ indirect effects on the dopaminergic ‘reward’ 
system, with such effects typically related to abuse and dependence liability (Schifano, 2014).In 
their animal study pregabalin appears to have the efficacy to counteract both reinforcing and 
withdrawal effects of opioids, but also have a potentiating effect when given to mice with 
existing opioid levels (Vashchinkina et al., 2017). This enhances patient and pregabalin user 
vulnerabilities to development of abuse patterns and dependence, particularly among opioid 
dependent patients. Other studies raise concern around poly use with methadone (Baird et al., 
2013) and other opiates (Loftus & Wright, 2014). Targetted awareness and support interventions 
are warranted (Yazdi et al., 2015; Evoy et al., 2017). 
Limitations 
The scoping review represents an initial step in mapping extant literature around what is known 
about misuse and abuse of pregabalin. Included records derive from retrospective reviews, 
survey data, and case reports. The review is hampered by difficulties in establishing accurate 
prevalence data, and the cases where pregabalin and gabapentin were analysed together.  
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Conclusion 
The scoping review presents available literature around misuse and abuse of pregabalin. Risk of 
pregabalin misuse and abuse is especially evidnet among patients with a history of substance 
abuse, those with psychiatric disorders and those who are opioid dependent. Physicians, their 
patients, and pharmacists all play a role in identifying, preventing and addressing pregabalin 
abuse and dependence (NIDA, 2014). The review highlights the need for enhanced surveillance, 
regulatory efforts, prescriber and pharmacy vigilance.  
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Figure. 1 Flow chart of the search strategy used during the scoping review of pregabalin 
abuse 
1,320 articles identified through 
database searching ( 4 duplicates 
removed). 
1,256 records excluded for lack of 
relevance specifically to the abuse 
potential of pregabalin, and animal 
studies. 
60 articles screened for 
inclusion criteria. 
4 duplicates 
removed. 
7 articles where full 
text were not available 
removed. 
3 articles not in 
English removed. 
Final number of records 
charted  N= 54 
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Table 1 A summary of all literature published about the abuse of pregabalin 
Authors Year/ country Method Summary of Findings Conclusion 
1. Filipetto et al. 2010/ New Jersey, USA A case report. A 35-year old woman with 
opioid  history, prescribed 
pregabalin for pain control. 
After her physician denied 
her request, subsequently 
obtained pregabalin from 
other sources. Over a 28-
day period the patient 
received a total of 88,500 
mg of pregabalin. 
This the first report 
diagnosed as a case of 
pregabalin abuse and 
referred to a local 
detoxification center. 
2. Aldemir et al. 2015/ Turkey A case report. A 34 year old man with a 
history of alcohol and 
poly-substance 
Pregabalin should be used 
carefully in patients with a 
history of substance 
Page 26 of 60
http://mc.manuscriptcentral.com/jdi
Journal of Drug Issues
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
dependence, and 
symptoms of GAD. He 
developed pregabalin 
dependence, then he 
experienced withdrawal 
symptoms when he tried to 
stop the drug. 
dependence. 
3. Yazdi et al. 2015/ Austria A case report. A male patient in his late 
20s with GAD and a 
history of alcohol and 
benzodiazepine abuse. He 
exhibited similar drug-
seeking behavior with 
pregabalin. With a daily 
intake 1050 mg. When 
there was no access to 
pregabalin, he experienced 
need for an intense 
awareness when 
prescribing pregabalin to 
an individual with alcohol 
or benzodiazepine 
addiction. 
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withdrawal symptoms. 
4. Driot et al. 2016/France A case report. A young female using 
pregabalin for anxiety, no 
history of substance abuse. 
But concurrent use with 
tobacco lead to synergic 
effect with craving for 
pregabalin, tolerance and 
withdrawal symptoms at 
usual doses (below 300 mg 
per day). 
Authors concluded that 
health professionals should 
be conscious of this 
potential risk of 
concomitant use with 
tobacco in patients with no 
history of substance use 
disorder, submitting a 
psychiatric condition, and 
specifically, addiction 
susceptibility. 
5. Papazisis et al. 2013/Greece A case report. A 19 year old man with a 
history of cannabis and 
alcohol abuse shows drug-
seeking behavior with 
pregabalin. He used it for 
This report highlights the 
abuse potential of 
pregabalin in a patient with 
a history of substance-
seeking behavior. 
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GAD, until he reached a 
dose of 1800 mg/day. 
A better clarification of its 
abuse potential is essential. 
As considering that the 
drug has recently been 
proposed as a treatment for 
alcohol- and 
benzodiazepine-
dependence. 
6. Carrus & Schifano 2012/Italy Two case reports A male patients in his first 
30s.Consumption of large 
dosages of pregabalin, 
(4500 mg) assumptions of 
drug smoking of the 
crushed tablet, and the 
possible incidence of 
myositis after pregabalin 
ingestion. Also sudden 
Potential of pregabalin for 
diversion as rapid 
development of high 
tolerance and withdrawal 
signs and symptoms upon 
discontinuation, which 
may be a matter of 
particular interest and 
doctors should carefully 
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stop of pregabalin, 
developed withdrawal 
symptoms that indicate its 
liability for physical 
dependence. 
assess patients for a history 
of drug abuse and monitor 
them for signs of 
pregabalin abuse. 
7. Grosshans et al. 2013/Germany Quantitative study A urine specimens were 
taken from 124 patients 
with opiate dependence 
and from 111 patients with 
other addiction disorders 
(alcohol, benzodiazepines, 
cannabis, amphetamines) 
were screened for 
pregabalin by means of a 
mass spectrometer 
analysis. To measure 
pregabalin abuse potential 
Only 12.1% of all urine 
specimens from patients 
with opiate addiction to be 
positive for pregabalin 
without medical purpose 
for pregabalin use with a N 
=11of 15, bought it from 
other heroin addicts or 
drug dealers. The authors 
concluded that pregabalin 
is liable to be abused 
among individuals with 
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in these patients. opiate dependency 
syndrome and more 
cautious about this issue 
must be taken. 
8. Loftus & Wright 2014/UK Observational study The author summarizes the 
drugs that used to manage 
neuropathic pain 
(pregabalin, gabapentin) 
for its potential misuse. As 
a suggestion that patients 
at high risk of addiction 
were prescribed higher 
than the recommended 
dose of pregabalin. 
Reported that when used 
alongside opiates to 
potentiate opiate effects 
are increasing. Also can be 
used alone in higher than 
recommended doses to 
produce sedation and 
psychedelic effects. The 
author concluded that the 
quantities supplied should 
be limited because of the 
possibility of misuse. 
9. Bodén et al. 2014/Sweden To identify patient’s About 8.5 % were The author concluded that 
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dispensed pregabalin at 
higher than the maximum 
accepted dose in a cohort 
study based on data 
derived from Swedish 
national registers. 
dispensing pregabalin in a 
dose that overridden the 
maximum daily accepted 
dose (600 mg). 
patients at a high danger of 
addiction and patients with 
epilepsy are more possible 
to be dispensed pregabalin 
at higher than the 
maximum allowed daily 
dose. 
10. Schjerning et al. 2016/ Denmark Observational study Using the Danish 
nationwide registers. To 
measure the predictor’s 
pregabalin use above 
recommended dosage and 
to investigate the trends in 
the use of pregabalin. A 
total of 42 520 pregabalin 
users 4 090 (9.6 %) were 
treated with more than 600 
The author concluded that 
use of pregabalin in 
Denmark increased 7-fold 
from its inception in 2004 
to 2013. Use of pregabalin 
above recommended dose 
is uncommon. The 
physician should pay 
attention to signs of abuse 
when prescribing 
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mg/day for 6 months and 
2 765 (6.5 %) for more 
than 12 months. Also a 
male gender and 
prescription of 
antipsychotics and 
benzodiazepines were 
correlated with increased 
risk of use of above the 
recommended dosage. 
pregabalin to patients 
already taking 
benzodiazepines, 
antipsychotics or opioids. 
11. Baird et al. 2013/UK A questionnaire-based 
survey 
Carried out in six 
substance misuse clinics, 
looking for evidence of 
gabapentinoid abuse. A 
total of 22% (29/129) of 
respondents admitted to 
abusing gabapentinoids, 
The study concludes  that 
clinicians should be aware 
of the potential for 
gabapentinoid abuse, and 
of the apparent effects of 
their abuse along with 
methadone. 
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and of these, 38% (11/29) 
abused gabapentinoids in 
order to potentiate the 
‘high’ they obtained from 
methadone. 
12. Schwan et al. 2010/Sweden Quantitative study Apply a Bayesian data-
mining algorithm to 
reports of possible drug 
abuse or addiction in the 
Swedish national register 
of adverse drug reactions 
(SWEDIS), and calculate 
the information component 
(IC) for pregabalin and 
reports of abuse and 
addiction. To investigate 
abuse potential of 
The author concludes that 
pregabalin is likely to be 
associated with an abuse 
liability and that further 
studies are urgently needed 
to characterize its extent 
and nature. 
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pregabalin. A total of 198 
reports indicate of abuse or 
addiction to any drug, only 
16 reports concerned 
pregabalin. 
13. Skopp & Zimmer 2011/ Germany A case report of pregabalin 
misuse. Pregabalin was 
analyzed by LC/MS/MS 
following precipitation of 
serum proteins. Vigabatrin 
was used as internal 
standard. 
A concentration of 25 pg 
pregabalin/mL serum 
determined in the present 
case is the second highest 
value published so far after 
misuse of the substance. 
The author concluded that 
additional studies are 
needed to assess the actual 
abuse potential of 
pregabalin. 
14. Schjerning et al. 2016/ Denmark A systemic review study Perform a systematic 
literature search and 
reviewed the preclinical, 
clinical and 
epidemiological data on 
The author concluded that 
the available literature 
suggests an important 
clinical abuse potential of 
pregabalin and prescribers 
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the abuse potential of 
pregabalin. A total of (n = 
17) preclinical, (n = 19)
clinical and (n = 13) 
epidemiological studies 
addressing the abuse 
potential of pregabalin. 
Also reviewed case reports 
(n = 9) concerning abuse 
of pregabalin. 
should pay attention to 
signs of abuse, especially 
in patients with a history of 
substance abuse. 
15. Papazisis et al. 2014/USA A systemic review study To review all published 
data signaling pregabalin’s 
abuse liability considering 
on the pharmacological 
characteristics. Result in 
different article, case 
series, screening study and 
The author concluded that 
is essential to make a good 
illustration of pregabalin 
abuse potential and further 
studies are essentially 
needed to identify the 
pathophysiological and 
Page 36 of 60
http://mc.manuscriptcentral.com/jdi
Journal of Drug Issues
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
several case reports. molecular basis of the 
setting pharmacological 
features that pregabalin 
shares with addictive 
drugs. 
16. Bossard et al. 2016/France A case/non case study was 
performed in the FPVD . 
A total of 184,310 reports 
in the database, 521 were 
abused or dependence 
cases. Among theme 8 
cases (1.5 %) concerned 
pregabalin, 18 cases (3.5 
%) clonazepam and 0 case 
amitriptyline. No 
statistically significant 
association between 
pregabalin and abuse or 
dependence was observed 
That pregabalin abuse 
potential still an issue that 
clinicians should recognize 
when prescribing this drug. 
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in the disproportionality 
analysis. 
17. Millar et al. 2013/UK Observational study A one year review of all 
patients presenting to the 
emergency department 
after recreational drug 
abuse of pregabalin. A 
total of 10 patients 
presented to the ED 
following recreational 
pregabalin abuse with a 
dosages ranged from 500–
1400 mg. 
The author concluded that 
emergency physicians 
should be aware of the 
current use of pregabalin 
as a recreational drug. 
18. Gahr et al. 2013/Germany Quantitative study A query of the entire 
database of the German 
Federal Institute for Drugs 
and Medical Devices 
The author concluded that 
the cases of pregabalin 
abuse or dependence 
reported in the BfArM 
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(BfArM) regarding reports 
of pregabalin abuse or 
dependence. A total of 55 
reports of pregabalin abuse 
or dependence were 
identified (mean age 36 
years, 64 % of the reports 
involved males). With a 
daily pregabalin dosage 
was 1424 mg. 
since 2008, and 
increasing. Male sex and a 
history of polytoxicomania 
may be possible risk 
factors for the 
development of addictive 
behaviors related to 
pregabalin. 
19. Häkkinen et al. 2014/ Finland Observational study They examined all medico 
legal death cases in 
Finland in which 
pregabalin or gabapentin 
was formed in postmortem 
toxicology during 2010–
2011. A  total of 316 cases 
The author concluded that 
in postmortem material, 
pregabalin was a more 
common finding than 
gabapentin and pregabalin 
abuse with large doses is 
increasingly frequent and 
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were pregabalin and 43 
cases were gabapentin. 
Drug abuse was combined 
with 48.1% of the 
pregabalin and 18.6% of 
the gabapentin findings. 
can be fatal when mixed 
with opioids. 
20. Kriikku et al. 2014/ Finland Quantitative study The samples were 
analyzed by an LC–
MS/MS system and the 
results were compared 
with the typical therapeutic 
range of pregabalin also 
the age and gender of the 
driver. A total of 206 
samples from pregabalin 
was detected. In about 
50% of the cases the serum 
The author concluded that 
pregabalin is being used in 
large doses, apparently for 
recreational purposes. Also 
that pregabalin contributed 
in their driving 
deterioration, but to what 
extent stayed unclear. 
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concentration was higher 
the typical therapeutic 
range. 
21. Kapil et al. 2014/UK Internet-based survey 
study 
To evaluate the 
prevalence, frequency and 
sources of misuse of the 
GABA analogues 
(baclofen, gabapentin and 
pregabalin). A total of 
1500 individuals was 
completed the online 
survey and the lifetime 
prevalence of misuse of 
any of the three surveyed 
GABA-analogue 
medications were 2.5% (n 
= 38); for each drug, this 
The author concluded that 
there is a definite misuse 
of baclofen, gabapentin 
and pregabalin in the UK, 
and we need further work 
to understand the reasons 
for misuse, to enable 
suitable targeted harm-
reduction activities by 
multi-agency responses. 
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was 1.3% (n = 19) for 
baclofen, 1.1% (n = 17) for 
gabapentin, and 0.5% (n = 
8) for pregabalin.
22. Wazaify et al. 2016/Jordan A questionnaire-based 
survey study 
To measure the 
abuse and misuse of drugs 
sold with or without a 
prescription in community 
pharmacies. New products 
have appeared on the list 
such as: ophthalmic drops 
(n=39, 13.4%) and the 
anti-epileptic; Lyrica 
(pregabalin; n=19, 6.5%). 
The author concluded that 
the patterns of suspected 
prescription and 
nonprescription drug 
abuse/misuse have slightly 
changed in Jordan over 
time, with the appearance 
of new drugs on the list 
which liable for abuse. 
23. Dart et al. 2017/USA Observational study, Data 
from the Nation Poison 
Data System were 
A total of 4152 Intentional 
Abuse cases revealed to 
gabapentin or pregabalin. 
The study concluded that 
the rates of intentional 
gabapentin and pregabalin 
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examined  for gabapentin 
and pregabalin product 
codes and were employed 
to decide if the category of 
Intentional Abuse cases 
were increasing in the US, 
and different outcomes 
from abusing them. 
The rate increased 4.3 fold 
between 2006 to 2014. 
Medical outcomes range 
from moderate effect, 
major to death. 
abuse has been increasing 
since 2006. 
24. Olaizola et al. 2006/Germany A case report A 44-year-old female used 
pregabalin for her 
neuropathic pain, after an 
unexpected increase in 
pregabalin dose, the 
patient suffers from 
psychotic symptoms  with 
rhythmic EEG-changes. 
After discontinuation of 
So physicians must be 
aware of psychotic 
symptoms in patients using 
pregabalin even in normal 
doses. 
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pregabalin the patient 
return to normal. 
25. Braga& Chidley 2006/UK A case report A 29-year-old male used 
lamotrigine and pregabalin 
in overdoses as he 
attempted to suicide by 
ingesting 32 g of 
lamotrigine and 11.5 g of 
pregabalin. 
So physicians must be 
aware of all anti-epileptic 
drugs adverse effects in 
both therapeutic and toxic 
doses. 
26. Wood et al. 2010/UK A case report A 54-year-old male 
presented to the 
Emergency Department 
(ED) after a self-reported 
ingestion of 8.4 g of 
pregabalin. Determined 
that the patient should be 
handled with airway and 
The highest reported serum 
pregabalin concentration in 
literature is in this patient, 
which is 66.5 mg/L. The 
physicians should be aware 
of this case of pregabalin 
toxicity to be treated with 
supportive care alone. 
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general supportive care 
alone, assuming a 
spontaneous  recovery. 
27. Yargic & Ozdemiroglu 2011/Turkey A case report A 37 year old man with a 
history of benzodiazepine 
and drug abuse, 
complaining of anxiety, 
then he used pregabalin 
and start to abuse it by 
taking 20 capsules to get 
euphoric. 
So physicians must be 
cautious when using 
pregabalin to treat patients 
with a history of drug 
abuse and that pregabalin 
having abuse potential 
lower than that of the 
benzodiazepines. 
28. Herman et al. 2012/USA Crossover study was 
obtained on 24 smokers in 
4 days treatment with 
pregabalin 300 mg or 
placebo, during the 
experiment the findings 
Pregabalin treatment in 
smokers didn’t lower the 
smoking behavior but it 
weakens some of smoking 
withdrawal symptoms and 
weaken the subjective 
Author concluded that 
pregabalin has fixed 
support as a treatment for 
smoking addiction. 
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were collected. To measure 
pregabalin's effects on 
smoking in general. 
ratings of “liking” in 
response to smoking. 
29. Zacny et al. 2012/USA A randomized, crossover 
study was conducted in 16 
healthy volunteers were 
grouped in five sessions 
taking capsules of placebo, 
75 mg pregabalin, 150 mg 
pregabalin, 10 mg 
oxycodone, and 75 mg 
pregabalin mixed with 10 
mg oxycodone. Then 
subjective, psychomotor, 
and physiological 
measures were evaluated. 
Pregabalin has no impact 
on psychomotor 
performance and has no 
increase on drug liking 
effects of the dose testing. 
While  oxycodone has an 
increase in drug liking 
effects. When mixed 
together drug liking of 
oxycodone was not 
elevated by 75 mg 
pregabalin. 
The author concluded that 
this drug is bused and need 
more 
psychopharmacological 
studies with pregabalin are 
allowed. 
30. Aksakal et al. 2012/Turkey A case report A 65-year-old woman This is the first report 
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admitted with dizziness 
and syncope that revealed 
she was taking pregabalin 
300 mg daily for 8 months 
for her neuropathic pain. 
On ECG found that there is 
complete atrioventricular 
(AV) blocked, once stoped 
using pregabalin the 
patient turn to normal. 
concluded there is effects 
of pregabalin on the heart. 
31. Gahr et al. 2014/Germany A meta-analysis study was 
conducted to all published 
cases, as a result of 
inadequate data in the 
evaluation of abuse 
liability of pregabalin is 
not finished, specifically 
Different cases and 
published literature. 
The author proposed that 
male sex, young age, and 
current or previous 
substance abuse may be 
risk factors that lead 
patients to become 
pregabalin correlated 
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the risk factors leading to 
the addictive behaviors. 
addictive behaviors. 
32. Tandon et al. 2013/India A case report A 21-year-old male patient 
taking pregabalin for his 
back pain with no history 
of drug abuse. After 
continuous use of 
pregabalin, the patient 
suffers from behavioral 
changes with self- harm in 
the forearm. 
From this reported side 
effect focuses the 
probability of abuse 
potential of pregabalin in 
young individuals and 
possible to cause self-harm 
behavior on a constant 
use. 
33. Gahr 2013/Germany A case report A 38-year-old female 
patient with borderline 
personality disorder and 
past alcohol abuse and 
nicotine dependence who 
become pregabalin abuse 
During the decline of 
pregabalin dose, the patient 
progressed a moderate 
withdrawal symptoms. 
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up to 600 mg/day. 
34. Wills et al. 2014/USA It is a retrospective study 
utilizing electronic poison 
center data, measuring 
clinical outcomes from 
newer anticonvulsant 
overdose. 
A total of 501 cases found, 
347 cases met the 
inclusion criteria, 23 cases 
of them were pregabalin. 
The author concluded that 
overdose of newer 
anticonvulsants leads to 
impaired mental status and 
there was no significant 
effect of dose on the 
intensity of outcome. No 
significant result regarding 
pregabalin. 
35. Osman & Casey 2014/Ireland A case report A 55-year-old male
patient with a history of 
various psychoactive 
substances abuse, later on 
he abused pregabalin as he 
used it for his anxiety by 
consuming 2250 mg/day in 
So physicians should be 
aware of prescribing 
pregabalin in patients with 
a history of substance 
abuse and more studies are 
needed regarding 
pregabalin and sexual 
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over 2 days. Then patient 
noticed an enhancement in 
sexual desire and 
excitement in 
psychological phase of the 
sexual response cycle, 
when using pregabalin in 
higher doses. 
cycle. 
36. Sonmez 2015/Turkey A case report A 31-year-old man with a 
history of drug abuse 
(cannabis, alcohol and 
others) and consuming 25–
30 capsules of pregabalin 
per day. Upon 
discontinuation of 
pregabalin the patient 
suffers from withdrawal 
So the report concluded 
that pregabalin is possibly 
abused for its positive 
psychological effects and 
should be cautiously used 
in patients with a history of 
substance use disorders. 
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symptoms and achieves the 
DSM-5 criteria for the 
pregabalin use disorder. 
37. Sugandiran&
Bramness 
2014/Norway Qualitative study, semi- 
structured interviews with 
six psychiatric patients at 
an outpatient clinic in 
Norway for a case series. 
The Norwegian version of 
M.I.N.I International 
Neuropsychiatric Interview 
was used to identify 
pregabalin abuse or 
dependence, according to 
DSM-IV diagnosis. 
Five of the six 
subjects achieved DSM-IV 
criteria for pregabalin 
dependence. All of these 
five patients had co-
morbid psychiatric 
conditions. 
The author concluded that 
patients with chronic 
disease has more or less 
dependence liability to 
their medication and 
proposed that the use of 
pregabalin may cause drug 
dependence without abuse. 
38. Wilens et al. 2014/USA A quality assurance 
program by assessing the 
A total of 162 patients 
admitted with opioid 
The author concluded that 
clinician working with 
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admitted patients in 
detoxification center, 
applying a self-report 
questionnaire to ask for 
particular psychotropic 
medication use, one of 
them pregabalin. 
dependency, 28% noted 
the use of medication in 
amounts higher than 
prescribed. Of opioid 
patients, 7% self- noted 
misusing pregabalin. 
opioid dependent patients 
should be cautious of the 
high levels of medication 
misuse of both controlled 
and non-controlled agents. 
39. Halaby 2015/Lebanone A case report A 26-year-old woman, 
who established 
dependence and 
withdrawal symptoms after 
stopping pregabalin as she 
abused it in a daily dose of 
1500–2400mg. 
After 6 weeks of treatment 
the patient turn to normal 
and this is the first report 
of pregabalin dependence. 
40. Suardi et al. 2016/ Switzerland Ten inpatients with 
pregabalin misuse were 
evaluated and regulate a 
All patients exist were 
having a history of drug 
abuse and pregabalin 
So pregabalin should be 
cautiously prescribed in 
patients have a history of 
Page 52 of 60
http://mc.manuscriptcentral.com/jdi
Journal of Drug Issues
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
systematic review of all 
published literature. 
misuse were by sniffing 
with a symptom of 
euphoria, psychomotor 
activation and sedation. 
drug abuse. 
41. Heikman et al. 2016/ Finland Two hundred urine 
samples collected from 82 
opioid maintenance 
treatment, patients were 
studied by liquid 
chromatography/time-of-
flight mass spectrometry 
screening method to detect 
the bused substances. 
Ninety-two (45.8%) 
samples were positive for 
the abused substances from 
the sample pregabalin was 
bused in 4.0%. 
The author reported all 
new psychoactive drugs 
that being recently abused 
and recognize these 
patients as a poly drug 
abuser. 
42. Eastwood & Davison 2016/UK The laboratory analyzes 
pregabalin concentration in 
post mortem blood to 
determine therapeutic and 
A total of 70 post-mortem 
blood samples of 
pregabalin was detected. 
Pregabalin concentrations 
The author concluded that 
most fetal condition as a 
result of multi-drug abuse 
and reported the highest 
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fatal ranges. ranged from 0.05 mg/L to 
226 mg/L in the group as a 
whole and in one case a 
pregabalin concentration of 
76 mg/L was detected to 
be the possible  cause of 
death as no other drugs of 
importance were included. 
pregabalin level in blood to 
date of 226 mg/L. 
43. Freynhagen et al. 2016/Germany A literature search of the 
MEDLINE and Cochrane 
Library databases were 
conducted with different 
keywords regarding 
dependence, withdrawal 
and pregabalin. 
There is limited data 
supporting pregabalin for 
managing of withdrawal 
symptoms, but the recent 
data are promising and 
more studies are needed 
regarding pregabalin safety 
and efficacy. 
So physician should be 
aware when prescribing 
pregabalin in patients with 
a history of substance 
abuse. 
44.Chiappini & Schifano 2016/ Italy All reports of both A total of 7639 reported The author concluded that 
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gabapentin and pregabalin 
relevant to abuse, misuse 
and dependence were 
analyzed and discussed. 
adverse drug reactions of 
pregabalin cases related to 
abuse, misuse and 
dependence. A total of 27 
deaths linked with 
pregabalin abuse, misuse 
and dependence. 
Proportional analysis 
reveals that adverse drug 
reactions are more frequent 
for pregabalin in 
comparison to gabapentin. 
gabapentinoids misuse 
may be a matter of interest, 
specifically in patients 
with previous history of 
drug misuse. 
45. Asomaning et al. 2016/UK An observational drug 
utilization study (DUS) 
analysis pregabalin 
prescription data from the 
UK Health Improvement 
A total of 13,480 patients, 
prescribing pregabalin was 
available. Only 1.0% of 
patients, prescribing 
pregabalin above 
The author concluded that 
most of pregabalin 
prescribing in the UK was 
symmetric with product 
labeling and the percent of 
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Network primary care 
database. 
maximum recommended 
dose 600 mg/day and 
18.4% of patients have a 
history of drug abuse. 
patients prescribing 
pregabalin in high doses 
was low. 
46. Martinotti 2012/Italy An observational study Pregabalin has high 
efficacy in psychiatric 
disorders as it useful in 
anxiety, but it has an abuse 
liability. 
As a conclusion that 
pregabalin at a dose above 
600 mg/day more seen in 
psychiatric conditions and 
an abuse potential of 
pregabalin is an issue of 
concern. 
47.Grosshans et al. 2010/Germany A case report A 47-year-old man with a 
history of drug and alcohol 
abuse who abuse 
pregabalin and become 
tolerant to it and has 
withdrawal symptoms 
So pregabalin may have an 
abuse liability and must be 
used cautiously in treating 
patient with previous drug 
abuse. 
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when he stop using it as he 
consume 25 capsules per 
day. 
48. Schifano et al. 2011/UK An analysis of both 
anecdotal online reports of 
pregabalin misuse and its 
online purchase 
availability levels. 
Pregabalin data were 
compared with related 
clonazepam and 
gabapentin online 
information. Qualitative 
Google searches of 203 
websites have been carried 
out in 8 European 
languages  using  specific 
A total of 52 websites was 
examined and 32 identified 
as relevant. More 
interesting findings of the 
present report is the 
dissociation effect noticed 
among 
pregabalin/gabapentin 
abusers and not in 
clonazepam abusers. 
The author concluded that 
an increase in online 
trafficking/debate about a 
specific psychoactive drug 
typically precedes the 
occurrence of clinical 
incidents at the population 
level and a careful of 
pregabalin misuse. 
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key words. 
49. Schifano 2014/UK An internet search of all 
available literatures was 
obtained and 
gabapentinoid 
experimenters are 
summarized here as 
individuals with a history 
of recreational polydrug 
misuse of higher doses. 
Different published 
literatures have obtained. 
So physicians should be 
aware of pregabalin misuse 
in a patient who has a 
history of drug abuse. 
50. Evoy et al. 2017/ USA A systemic review study Assessing the extent of 
gabapentinoid abuse, 
characteristics of typical 
abusers, patterns of abuse, 
and potential harms in 
order to bring this trend to 
providers’ awareness. 
Concluded that 
gabapentinoids possess 
potential for abuse, 
particularly in individuals 
with a history of opioid 
abuse. 
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51. Bonnet and Scherbaum 2017/Germany A systemic review study To evaluate gabapentinoid 
addiction risk in more 
detail. 
Cautious use of 
gabapentinoid in a patient 
with a history of substance 
use disorder. 
52. Al-Husseini et al. 2017/Jordan A qualitative study Semi-structured interviews 
were conducted to explore 
and describe pregabalin 
users' experiences. 
The study concluded that 
the problem of pregabalin 
abuse and misuse in 
Amman, Jordan, exists 
with many challenges and 
several complicating 
factors. 
53. Cossmann et al. 2016/Germany A cohort study An older patients in a 
German hospital (400 
randomly selected cases) 
reported that a fifth of the 
cohort was found to be 
dependent on nonopioid 
The study concluded that 
the identification and 
management of addiction 
disorders should be 
considered as part of the 
basic geriatric assessment. 
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analgesics, and with one 
case identified with a 
history of dependence on 
gabapentin. 
54. Mutschler et al. 2016/ Switzerland Quantitative study Pregabalin use among 
opioid-addicted patients 
were assessed in 109 cases 
and quantified using 3-
month hair toxicology 
analysis. 
None of the participants 
reported pregabalin use 
and pregabalin was 
undetectable in all 
samples. Also the study 
recommended more 
caution regarding 
pregabalin use when 
treating patients with a 
history of opioid 
dependence. 
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